The overall aim of PRISM 2 is to accelerate the development of effective treatments for patients suffering from neuropsychiatric disorders by implementing a quantitative, transdiagnostic neurobiological approach to the understanding of these disorders.
The following specific objectives will be addressed by the PRISM 2 project:
- Determine the reproducibility of the transdiagnostic and pathophysiological relationship between default mode network (DMN) integrity and social dysfunction in schizophrenia (SZ) and Alzheimer’s Disease (AD), and its potential to generalise to Major Depressive Disorder (MDD)
- Test the causality between the quantitative variation in DMN integrity and social dysfunction
- Translate and communicate the project’s results efficiently to all stakeholders for the benefit of patients and their families, regulators, health care providers, the general public, learned societies, and the pharmaceutical industry